Celgene's Revlimid hits goal in multiple myeloma study, stock jumps
This article was originally published in Scrip
Celgene said its blood cancer drug Revlimid met a study goal of treating newly diagnosed patients with multiple myeloma. Shares of the big US biotech company rose to a new record as investors saw the results as a path to higher sales for Celgene’s biggest drug.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.